Cargando…
Phase 1, randomized, parallel-group, double-blind, placebo-controlled trial to evaluate the effects of erenumab (AMG 334) and concomitant sumatriptan on blood pressure in healthy volunteers
OBJECTIVES: The aim of this study was to assess the effects of concomitant administration of erenumab and sumatriptan on resting blood pressure, pharmacokinetics, safety, and tolerability in healthy subjects. METHODS: In this phase 1, parallel-group, one-way crossover, double-blind, placebo-controll...
Autores principales: | de Hoon, Jan, Van Hecken, Anne, Vandermeulen, Corinne, Herbots, Marissa, Kubo, Yumi, Lee, Ed, Eisele, Osa, Vargas, Gabriel, Gabriel, Kristin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348461/ https://www.ncbi.nlm.nih.gov/pubmed/29783863 http://dx.doi.org/10.1177/0333102418776017 |
Ejemplares similares
-
Pharmacokinetic-Pharmacodynamic Relationship of Erenumab (AMG 334) and Capsaicin-Induced Dermal Blood Flow in Healthy and Migraine Subjects
por: Vu, Thuy, et al.
Publicado: (2017) -
EHMTI-0315. AMG 334, the first potent and selective human monoclonal antibody antagonist against the CGRP receptor
por: Xu, C, et al.
Publicado: (2014) -
Vascular safety of erenumab for migraine prevention
por: Kudrow, David, et al.
Publicado: (2020) -
Pre-treatment with sumatriptan for cilostazol induced headache in healthy volunteers
por: Falkenberg, Katrine, et al.
Publicado: (2018) -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers
por: Monteith, David, et al.
Publicado: (2017)